Characterization of the Kinetics of Renal Glucose Reabsorption in Response to Dapagliflozin in Healthy Subjects and in Subjects With Type 2 Diabetes Mellitus (T2DM)

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 31, 2010

Primary Completion Date

December 31, 2010

Study Completion Date

December 31, 2010

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG

Dapagliflozin

Tablets, Oral, 10 mg, Once daily, 7 days

Trial Locations (1)

Profil Institute For Clinical Research, Inc., Chula Vista